Q1 EPS Forecast for Microbot Medical Increased by Analyst

Microbot Medical Inc. (NASDAQ:MBOT) – HC Wainwright lifted their Q1 2025 earnings estimates for Microbot Medical in a research report issued on Thursday, April 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.40) EPS.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Microbot Medical Stock Performance

MBOT stock opened at $2.28 on Monday. The firm has a market cap of $79.22 million, a P/E ratio of -2.85 and a beta of 1.40. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38. The stock has a 50-day simple moving average of $1.68 and a 200-day simple moving average of $1.39.

Institutional Trading of Microbot Medical

A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC bought a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned approximately 0.52% of Microbot Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.